Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study
DOI:
https://doi.org/10.2340/1651-226X.2024.40325Keywords:
High-grade serous ovarian carcinoma, real-world evidence, treatment patterns, time to next treatment, progression-free survival, bevacizumab, prognostic factorsAbstract
Background: As the treatment landscape for advanced ovarian cancer (OC) evolves, it is important to understand patient outcomes in real-world clinical practice. OCRWE-Finland was an observational cohort study investigating OC outcomes, including treatment patterns, time to next treatment 1 (TTNT1), overall survival and healthcare resource utilisation, in Finland during the pre-PARPi era.
Materials and methods: Patients included in OCRWE-Finland were diagnosed with OC between 2014 and 2019. Here, we report treatment patterns and TTNT1 outcomes (as a surrogate for progression-free survival) for patients in the high-grade serous ovarian carcinoma (HGSOC) cohort.
Results: In OCRWE-Finland, there were 867 patients with HGSOC. Of the 811 patients who received first-line treatment, the most common regimen was surgery and adjuvant chemotherapy (53%), and 227 patients also received first-line bevacizumab. Median TTNT1 among 623 patients with stage III/IV disease was 19 months (95% confidence interval, 18–21 months), with no difference between patients with stage III or IV disease (p = 0.24). The presence versus absence of visible residual disease post-debulking surgery was associated with shorter TTNT1 among patients with stage III tumours (p = 0.031) but showed no impact for stage IV tumours (p = 0.55). First-line versus no first-line bevacizumab was associated with shorter TTNT1 among stages I–IV (p < 0.0001) but did not affect patients with stage III/IV tumours (p = 0.45).
Interpretation: In the pre-PARPi era, prognosis for advanced OC was poor, particularly for patients with stage III tumours and visible residual disease or stage IV tumours regardless of the presence of residual disease. The increasing use of PARPis will hopefully help address the need for effective treatments in advanced OC.
Downloads
References
Finnish Cancer Registry. Ovarian cancer fact sheet. 2020 [cited 2023 Jan 31]. Available from: https://syoparekisteri.fi/assets/themes/ssy3/factsheets/syopien-tietolaatikot/28en_Ovary.html
Matulonis UA. Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018 Jun;16(6):426-37.
Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review. J Ovarian Res. 2022 Jul 28;15(1):88.
https://doi.org/10.1186/s13048-022-01020-1 DOI: https://doi.org/10.1186/s13048-022-01020-1
González-Martín A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833-48.
https://doi.org/10.1016/j.annonc.2023.07.011 DOI: https://doi.org/10.1016/j.annonc.2023.07.011
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:24-32.
https://doi.org/10.1093/annonc/mdt333 DOI: https://doi.org/10.1093/annonc/mdt333
Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5(1):1197.
https://doi.org/10.1186/s40064-016-2660-0 DOI: https://doi.org/10.1186/s40064-016-2660-0
Ray-Coquard I, Mirza MR, Pignata S, Walther A, Romero I, du Bois A. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: comparison of active surveillance and maintenance treatment. Cancer Treat Rev. 2020 Nov;90:102107.
https://doi.org/10.1016/j.ctrv.2020.102107 DOI: https://doi.org/10.1016/j.ctrv.2020.102107
Finnish Gynecological Oncology Specialists. Treatment recommendations 2022 [cited 2023 Jan 05]. Available from: https://gynekologiyhdistys.fi/wp-content/uploads/2022/08/fingogkelpohoito2022.pdf
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928-36.
https://doi.org/10.1016/S1470-2045(15)00086-8 DOI: https://doi.org/10.1016/S1470-2045(15)00086-8
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019 May 1;30(5):672-705.
Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, et al. Real-life data on treatment and outcomes in advanced ovarian cancer: an observational, multinational cohort study (RESPONSE trial). Cancer. 2022 Aug 15;128(16):3080-9.
https://doi.org/10.1002/cncr.34350 DOI: https://doi.org/10.1002/cncr.34350
Lindemann K, Abreu M, Batarda MdL, Boll D, Ekmann-Gade AW, Hansen J, et al. Ovarian cancer and bevacizumab: real-world use across western countries and effect on survival in high-risk subgroups. J Clin Oncol. 2023;41(16_suppl):5587.
https://doi.org/10.1200/JCO.2023.41.16_suppl.5587 DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.5587
European Medicines Agency. Zejula (niraparib) 100 mg hard capsules: summary of product characteristics. 2017 [updated 2022; cited 2023 Jan 31]. Available from: https://www.ema.europa.eu/en/documents/product-information/zejula-epar-product-information_en.pdf
European Medicines Agency. Lynparza (olaparib): summary of product characteristics 2015 [updated 2022; cited 2023 Jan 31]. Available from: https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf
Fameli A, Paulsson T, Altimari S, Gutierrez B, Cimen A, Nelsen L, et al. Looking beyond survival data: how should we assess innovation in oncology reimbursement decision making 2023 [cited 2023 Sep 28]. Available from: https://www.ispor.org/publications/journals/value-outcomes-spotlight
Walker MS, Herms L, Miller PJE. Performance of time to discontinuation and time to next treatment as proxy measures of progression-free survival, overall and by treatment group. J Clin Oncol. 2020;38(15_suppl):e19135-e.
https://doi.org/10.1200/JCO.2020.38.15_suppl.e19135 DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.e19135
Chase DM, Mahajan A, Scott DA, Hawkins N, Kalilani L. Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review. Int J Gynecol Cancer. 2023;33(10):1602-11.
https://doi.org/10.1136/ijgc-2023-004487 DOI: https://doi.org/10.1136/ijgc-2023-004487
Walker B, Boyd M, Aguilar K, Davies K, Espirito J, Frytak J, et al. Comparisons of real-world time-to-event end points in oncology research. JCO Clin Cancer Inform. 2021 Jan;5:45-6.
https://doi.org/10.1200/CCI.20.00125 DOI: https://doi.org/10.1200/CCI.20.00125
Campbell BA, Dobos G, Haider Z, Prince HM, Bagot M, Evison F, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):6639-47.
https://doi.org/10.1182/bloodadvances.2023011041 DOI: https://doi.org/10.1182/bloodadvances.2023011041
Lahelma M, Rauhamaa H, Leskelä R-L, Isomeri O, Idänpään-Heikkilä J, Käkelä S et al. Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: The OCRWE-Finland Study. Acta Oncol. 2024;63: 763-71.
https://doi.org/10.2340/1651-226X.2024.40324 DOI: https://doi.org/10.2340/1651-226X.2024.40324
Badgwell D, Bast RC, Jr. Early detection of ovarian cancer. Dis Markers. 2007;23(5-6):397-410.
https://doi.org/10.1155/2007/309382 DOI: https://doi.org/10.1155/2007/309382
Zachou G, El-Khouly F, Dilley J. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2023 Aug 31;8(8):Cd006119.
https://doi.org/10.1002/14651858.CD006119.pub4 DOI: https://doi.org/10.1002/14651858.CD006119.pub4
Segev Y, Gemer O, Auslender R, Lavie O. Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate. Harefuah. 2014 Sep;153(9):527-31, 58.
Mandato VD, Aguzzoli L. Management of ovarian cancer during the COVID-19 pandemic. Int J Gynaecol Obstet. 2020 Jun;149(3):382-3.
https://doi.org/10.1002/ijgo.13167 DOI: https://doi.org/10.1002/ijgo.13167
Takamatsu S, Nakai H, Yamaguchi K, Hamanishi J, Mandai M, Matsumura N. Time-dependent changes in risk of progression during use of bevacizumab for ovarian cancer. JAMA Netw Open. 2023 Aug 1;6(8):e2326834.
https://doi.org/10.1001/jamanetworkopen.2023.26834 DOI: https://doi.org/10.1001/jamanetworkopen.2023.26834
Dewdney S, Potter D, Haidle JL, Hulick PJ, Riffon M, Monzon FA, et al. Low rates of BRCA1 and BRCA2 testing for patients with ovarian cancer in ASCO's CancerLinQ, a real-world database. J Clin Oncol. 2020;38(15_suppl):6041.
https://doi.org/10.1200/JCO.2020.38.15_suppl.6041 DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.6041
Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2017 Jan 3;8(1):285-302.
https://doi.org/10.18632/oncotarget.12306 DOI: https://doi.org/10.18632/oncotarget.12306
Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim D, et al. Ovarian Real-World International Consortium (ORWIC): a multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Front Oncol. 2023;13:1114435.
https://doi.org/10.3389/fonc.2023.1114435 DOI: https://doi.org/10.3389/fonc.2023.1114435
Shukla S, Xiang C, Kobayashi M, Valliant SN, Begaj K, Gao S, et al., editors. Correlation between real-world progression-free survival and other outcomes among patients with ovarian cancer who received poly(ADP-ribose) polymerase inhibitors in the first-line maintenance setting. San Diego: Society for Gynecologic Oncology (SGO); 2024.
https://doi.org/10.1016/j.ygyno.2024.07.309 DOI: https://doi.org/10.1016/j.ygyno.2024.07.309
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Mari Lahelma, Heini Rauhamaa, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen
This work is licensed under a Creative Commons Attribution 4.0 International License.
